Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastroenteropancreatic Neuroendocrine Carcinoma”

33 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 33 results

Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals 116
Testing effectiveness (Phase 2)Study completedNCT02611024
What this trial is testing

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Who this might be right for
Advanced Solid TumorsGlioblastomaSoft Tissue Sarcoma (Excluding GIST)+9 more
PharmaMar 316
Testing effectiveness (Phase 2)Study completedNCT03591731
What this trial is testing

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

Who this might be right for
Neuroendocrine Carcinoma
Intergroupe Francophone de Cancerologie Thoracique 185
Testing effectiveness (Phase 2)WithdrawnNCT03901378
What this trial is testing

Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma

Who this might be right for
Neuroendocrine CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungHigh Grade Neuroendocrine Carcinoma, Any Site
Ochsner Health System
Testing effectiveness (Phase 2)Active Not RecruitingNCT06790706
What this trial is testing

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

Who this might be right for
Peritoneal MesotheliomaGestational Trophoblastic TumorAnaplastic Thyroid Carcinomas+3 more
Hospices Civils de Lyon 27
Early research (Phase 1)Study completedNCT05262556
What this trial is testing

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine NeoplasmNeuroendocrine Carcinoma+1 more
Amr Mohamed MD 15
Early research (Phase 1)Looking for participantsNCT07080242
What this trial is testing

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Who this might be right for
Small Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine CancerMetastatic Neuroendocrine Prostate Cancer+8 more
SystImmune Inc. 120
Early research (Phase 1)Looking for participantsNCT07006727
What this trial is testing

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Who this might be right for
Small Cell Lung CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungNeuroendocrine Prostate Cancer+8 more
Novartis Pharmaceuticals 116
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05385861
What this trial is testing

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

Who this might be right for
GEP-NET
National Health Research Institutes, Taiwan 52
Not applicableActive Not RecruitingNCT05064150
What this trial is testing

Neuroendocrine Tumors - Patient Reported Outcomes

Who this might be right for
Neuroendocrine TumorsGastroenteropancreatic Neuroendocrine TumorLung Neuroendocrine Neoplasm+1 more
University of Iowa 2,539
Early research (Phase 1)Not Yet RecruitingNCT07661420
What this trial is testing

211At-MABG in Adults With Advanced Neuroendocrine Cancers

Who this might be right for
PheochromocytomaParagangliomaNeuroendocrine Tumors+3 more
University of Pennsylvania 16
Testing effectiveness (Phase 2)Looking for participantsNCT04325425
What this trial is testing

Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

Who this might be right for
Neuroendocrine Carcinoma
Centre Hospitalier Universitaire Dijon 218
Large-scale testing (Phase 3)Study completedNCT00690430
What this trial is testing

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Who this might be right for
Symptomatic Refractory Resistant Carcinoid Disease
Novartis Pharmaceuticals 186
Testing effectiveness (Phase 2)Active Not RecruitingNCT02595424
What this trial is testing

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Who this might be right for
Gastric Neuroendocrine CarcinomaIntestinal Neuroendocrine CarcinomaPancreatic Neuroendocrine Carcinoma
ECOG-ACRIN Cancer Research Group 67
Testing effectiveness (Phase 2)UnknownNCT03475953
What this trial is testing

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Who this might be right for
Colorectal Cancer Not MSI-H or MMR-deficientGISTOesophageal or Gastric Carcinoma+12 more
Institut Bergonié 747
Testing effectiveness (Phase 2)UnknownNCT02687958
What this trial is testing

Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin

Who this might be right for
Neuroendocrine Carcinoma
Gruppo Oncologico Italiano di Ricerca Clinica 30
Testing effectiveness (Phase 2)Study completedNCT02250885
What this trial is testing

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Who this might be right for
Carcinoma, Neuroendocrine
Gabrail Cancer Center Research 14
Testing effectiveness (Phase 2)Study completedNCT03079440
What this trial is testing

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsNeuroendocrine CarcinomaTemozolomide+1 more
Asan Medical Center 31
Testing effectiveness (Phase 2)Looking for participantsNCT05652686
What this trial is testing

Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Who this might be right for
Small Cell Lung Cancer (SCLC)Large Cell Neuroendocrine Cancer (LCNEC)Neuroendocrine Prostate Cancer (NEPC)+3 more
Phanes Therapeutics 203
Testing effectiveness (Phase 2)Ended earlyNCT03042780
What this trial is testing

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Who this might be right for
Gastro-enteropancreatic Neuroendocrine TumorPancreatic CancerNeuroendocrine Carcinomas of Pancreas+1 more
H. Lee Moffitt Cancer Center and Research Institute 2
Next Page